<DOC>
	<DOCNO>NCT00041210</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat patient advance Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness two different combination chemotherapy regimens treat patient advance Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Previously Untreated Advanced Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare relapse-free overall survival patient previously untreated advanced Hodgkin 's lymphoma treat bleomycin , doxorubicin , etoposide , mechlorethamine , vinblastine , vincristine , prednisone ( Stanford V ) v doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( Stanford V ) : Patients receive mechlorethamine week 1 , 5 , 9 ; vinblastine doxorubicin week 1 , 3 , 5 , 7 , 9 , 11 ; etoposide IV 30-45 minute 2 consecutive day week 3 , 7 , 11 ; vincristine bleomycin week 2 , 4 , 6 , 8 , 10 , 12 . Patients also receive oral prednisone every day day 1-63 followed taper day 64-84 . Treatment continue 12 week . - Arm II ( ABVD ) : Patients receive doxorubicin , bleomycin , vinblastine , dacarbazine day 1 15 . Treatment repeat every 28 day 6-8 course . All patient achieve complete remission partial remission chemotherapy undergo involve field radiotherapy initial bulky mediastinal disease , initial nodal mass least 5 cm diameter , initial splenic disease . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 700-850 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma ( subtype ) Stage IB , IIB , IIIA , IIIB , IV OR Stage IA IIA locally extensive disease ( e.g. , bulky mediastinal disease ( e.g. , great 0.33 maximum transthoracic diameter routine chest Xray least 2 extranodal site disease ) ) PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Complete blood count normal unless directly due Hodgkin 's lymphoma Hepatic : Hepatic function normal unless directly due Hodgkin 's lymphoma Renal : Renal function normal unless directly due Hodgkin 's lymphoma Cardiovascular : No preexist cardiac disease Pulmonary : No preexist pulmonary disease Other : Not pregnant Fertile patient must use effective contraception six month study HIV negative No prior malignancy except basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy Hodgkin 's lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
</DOC>